Jennifer C Ho1, Pamela K Allen1, Anuja Jhingran1, Shannon N Westin2, Karen H Lu2, Patricia J Eifel1, Ann H Klopp3. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: aklopp@mdanderson.org.
Abstract
OBJECTIVE: Pelvic and paraortic lymph nodal regions are frequent sites of relapse in women with endometrial cancer who have not undergone adjuvant external beam radiation. We investigated outcomes after definitive management of nodal relapses of endometrial cancer with intensity modulated radiation therapy (IMRT). METHODS: Between 2002-2012, 38 patients with endometrial cancer who had no prior external beam radiation were treated definitively using IMRT for regionally confined pelvic or paraortic nodal recurrences. Thirteen (34%) had chemotherapy prior to radiation, and 21 (55%) received concurrent chemotherapy. The nodal basins were typically treated to 45-50Gy, with a boost to the gross tumor to a median total of 64.7Gy (range 59-73Gy). RESULTS: The median overall survival from date of recurrence was 46.1months and the 2-year survival was 71%. Patients who received concurrent chemotherapy had a significantly longer median survival (61.9months versus 28.7months, p=0.034). In-field failures were more frequent in patients who received chemotherapy prior to radiation, had a shorter recurrence-free interval, received a lower radiation dose, and had higher tumor grade. Three patients (8%) experienced grade 3-4 late gastrointestinal (GI) toxicity. CONCLUSIONS: Long-term survival can be achieved in women with nodal recurrences of endometrial cancer. The use of concurrent chemotherapy and dose escalation with IMRT as feasible may improve survival for women with isolated nodal recurrences of endometrial cancer.
OBJECTIVE: Pelvic and paraortic lymph nodal regions are frequent sites of relapse in women with endometrial cancer who have not undergone adjuvant external beam radiation. We investigated outcomes after definitive management of nodal relapses of endometrial cancer with intensity modulated radiation therapy (IMRT). METHODS: Between 2002-2012, 38 patients with endometrial cancer who had no prior external beam radiation were treated definitively using IMRT for regionally confined pelvic or paraortic nodal recurrences. Thirteen (34%) had chemotherapy prior to radiation, and 21 (55%) received concurrent chemotherapy. The nodal basins were typically treated to 45-50Gy, with a boost to the gross tumor to a median total of 64.7Gy (range 59-73Gy). RESULTS: The median overall survival from date of recurrence was 46.1months and the 2-year survival was 71%. Patients who received concurrent chemotherapy had a significantly longer median survival (61.9months versus 28.7months, p=0.034). In-field failures were more frequent in patients who received chemotherapy prior to radiation, had a shorter recurrence-free interval, received a lower radiation dose, and had higher tumor grade. Three patients (8%) experienced grade 3-4 late gastrointestinal (GI) toxicity. CONCLUSIONS: Long-term survival can be achieved in women with nodal recurrences of endometrial cancer. The use of concurrent chemotherapy and dose escalation with IMRT as feasible may improve survival for women with isolated nodal recurrences of endometrial cancer.
Authors: Jonathan Verma; Erik P Sulman; Anuja Jhingran; Susan L Tucker; Gaiane M Rauch; Patricia J Eifel; Ann H Klopp Journal: Int J Radiat Oncol Biol Phys Date: 2014-02-01 Impact factor: 7.038
Authors: Junzo P Chino; Ellen Jones; Andrew Berchuck; Angeles Alvarez Secord; Laura J Havrilesky Journal: Int J Radiat Oncol Biol Phys Date: 2011-06-02 Impact factor: 7.038
Authors: R A Nout; V T H B M Smit; H Putter; I M Jürgenliemk-Schulz; J J Jobsen; L C H W Lutgens; E M van der Steen-Banasik; J W M Mens; A Slot; M C Stenfert Kroese; B N F M van Bunningen; A C Ansink; W L J van Putten; C L Creutzberg Journal: Lancet Date: 2010-03-06 Impact factor: 79.321
Authors: Arno J Mundt; Anthony E Lujan; Jacob Rotmensch; Steven E Waggoner; S Diane Yamada; Gini Fleming; John C Roeske Journal: Int J Radiat Oncol Biol Phys Date: 2002-04-01 Impact factor: 7.038
Authors: J Northover; R Glynne-Jones; D Sebag-Montefiore; R James; H Meadows; S Wan; M Jitlal; J Ledermann Journal: Br J Cancer Date: 2010-03-16 Impact factor: 7.640
Authors: Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch Journal: J Clin Oncol Date: 2004-03-01 Impact factor: 44.544
Authors: Sarah A Milgrom; Marisa A Kollmeier; Nadeem R Abu-Rustum; Roisin E O'Cearbhaill; Richard R Barakat; Kaled M Alektiar Journal: Gynecol Oncol Date: 2014-05-27 Impact factor: 5.482
Authors: John A Vargo; Hayeon Kim; Serah Choi; Paniti Sukumvanich; Alexander B Olawaiye; Joseph L Kelley; Robert P Edwards; John T Comerci; Sushil Beriwal Journal: Int J Radiat Oncol Biol Phys Date: 2014-10-08 Impact factor: 7.038
Authors: Shervin M Shirvani; Ann H Klopp; Anna Likhacheva; Anuja Jhingran; Pamela T Soliman; Karen H Lu; Patricia J Eifel Journal: Pract Radiat Oncol Date: 2012-05-03
Authors: Aliyah Almomen; Elke A Jarboe; Mark K Dodson; C Matthew Peterson; Shawn C Owen; Margit M Janát-Amsbury Journal: Pharm Res Date: 2016-05-31 Impact factor: 4.200
Authors: Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu Journal: Virchows Arch Date: 2021-02 Impact factor: 4.064
Authors: E Leung; A Gladwish; A Sahgal; S S Lo; C A Kunos; R M Lanciano; C A Mantz; M Guckenberger; T M Zagar; N A Mayr; A R Chang; S Jorcano; T Biswas; A Pontoriero; K V Albuquerque Journal: Radiat Oncol Date: 2020-01-30 Impact factor: 3.481
Authors: Günter Emons; Clemens Tempfer; Marco Johannes Battista; Alexander Mustea; Dirk Vordermark Journal: Geburtshilfe Frauenheilkd Date: 2019-12-11 Impact factor: 2.915
Authors: Anne Sophie V M van den Heerik; Nanda Horeweg; Stephanie M de Boer; Tjalling Bosse; Carien L Creutzberg Journal: Int J Gynecol Cancer Date: 2020-10-20 Impact factor: 3.437
Authors: Heidi Rütten; Cornelia Verhoef; Willem Jan van Weelden; Anke Smits; Joëlle Dhanis; Nelleke Ottevanger; Johanna M A Pijnenborg Journal: Cancers (Basel) Date: 2021-12-14 Impact factor: 6.639